Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma Clinical Trial

Official title:

A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00082459
• Other study ID #: C-100-23
• Status: Terminated
• Phase: Phase 2
• First received: May 10, 2004
• Last updated: September 6, 2012
• Start date: July 2002
• Est. completion date: December 2005

Study information

• Verified date: September 2012
• Source: Agenus, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.

Description:

The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor. The study is being conducted in Houston, Texas with patients enrolled into one of two treatment arms. The two treatment arms are either subcutaneous injection or intradermal injection, both with HSPPC-96. To be treated with HSPPC-96 patients must undergo surgery to remove the kidney tumor and a portion of this tissue will be sent to Antigenics' manufacturing facility for processing.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: December 2005
• Est. primary completion date: December 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor

• No previous therapy for metastatic renal cell carcinoma

• Measurable disease (RECIST criteria)

• Primary tumor greater than or equal to 7cm on CT or MRI

• ECOG performance status 0-1

• At least 18 years old

• Life expectancy > 3 months

• Adequate cardiac function (NYHA I-II)

• Not pregnant

• Provide written informed consent

• Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features)

• Planned complete nephrectomy

Exclusion Criteria:

• History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A

• Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin)

• Embolization of the renal artery prior to nephrectomy

• Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Renal Cell Carcinoma

Intervention

Biological:
• autologous human tumor-derived HSPPC-96

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Agenus, Inc.

Country where clinical trial is conducted

United States,